| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2017 | Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients | Lee M.-H; | Huang C.-F; | Lai H.-C; | Lin C.-Y; | Dai C.-Y; | Liu C.-J; | Wang J.-H; | Huang J.-F; | Su W.-P; | HUNG-CHIH YANG ; | Kee K.-M; | Yeh M.-L; | Chuang P.-H; | Hsu S.-J; | Huang C.-I; | Kao J.-T; | Chen C.-C; | Chen S.-H; | Jeng W.-J; | Yang H.-I; | Yuan Y; | Lu S.-N; | Sheen I.-S; | Liu C.-H; | Peng C.-Y; | Kao J.-H; | Yu M.-L; | Chuang W.-L; | Chen C.-J. | Scientific Reports | |||
| 2013 | Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion | HUNG-CHIH YANG ; | Chen C.-L; | Shen Y.-C; | Peng C.-Y; | Liu C.-J; | Tseng T.-C; | Su T.-H; | Chuang W.-L; | Yu M.-L; | Dai C.-Y; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H. | Hepatology | |||
| 2015 | Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial | Liu C.-H; | Huang C.-F; | Liu C.-J; | Dai C.-Y; | Huang J.-F; | Lin J.-W; | Liang C.-C; | Yang S.-S; | Lin C.-L; | Su T.-H; | HUNG-CHIH YANG ; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Kao J.-H; | Yu M.-L. | Scientific Reports | |||
| 2015 | Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial | Liu C.-H; | Liu C.-J; | Huang C.-F; | Lin J.-W; | Dai C.-Y; | Liang C.-C; | Huang J.-F; | Hung P.-H; | Tsai H.-B; | Tsai M.-K; | Lee C.-Y; | Chen S.-I; | Yang S.-S; | Su T.-H; | HUNG-CHIH YANG ; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Yu M.-L; | Kao J.-H. | Gut | |||
| 2015 | Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial | Liu C.-H; | Huang C.-F; | Liu C.-J; | Dai C.-Y; | Huang J.-F; | Lin J.-W; | Liang C.-C; | Yang S.-S; | Lin C.-L; | Su T.-H; | HUNG-CHIH YANG ; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Kao J.-H; | Yu M.-L. | Scientific Reports | |||
| 2013 | Pegylated interferon-�\2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial | Liu C.-H; | Huang C.-F; | Liu C.-J; | Dai C.-Y; | Liang C.-C; | Huang J.-F; | Hung P.-H; | Tsai H.-B; | Tsai M.-K; | Chen S.-I; | Lin J.-W; | Yang S.-S; | Su T.-H; | HUNG-CHIH YANG ; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Yu M.-L; | Kao J.-H. | Annals of Internal Medicine | |||
| 2013 | Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up | Yu M.-L; | Lee C.-M; | Chen C.-L; | Chuang W.-L; | Lu S.-N; | Liu C.-H; | Wu S.-S; | Liao L.-Y; | Kuo H.-T; | Chao Y.-C; | Tung S.-Y; | Yang S.-S; | Kao J.-H; | Su W.-W; | Lin C.-L; | HUNG-CHIH YANG ; | Chen P.-J; | Chen D.-S; | Liu C.-J. | Hepatology |
